Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (3y) (2015 - 2024)
Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (3y) (2015 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 16.27% |
| 10 | Acadia Pharmaceuticals | 4.36 Bn | 3.51 Bn | 243.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 668.01% |
| Dec 31, 2021 | -87.61% |
| Jun 30, 2021 | -26.86% |
| Mar 31, 2021 | 33.92% |
| Dec 31, 2020 | 558.52% |
| Sep 30, 2020 | 213.23% |
| Jun 30, 2020 | 123.14% |
| Mar 31, 2020 | 24.41% |
| Dec 31, 2019 | -5.97% |
| Sep 30, 2019 | -44.58% |
| Jun 30, 2019 | -67.45% |
| Mar 31, 2019 | 58.36% |
| Dec 31, 2018 | 21.54% |
| Sep 30, 2018 | 76.06% |
| Jun 30, 2018 | -44.54% |
| Mar 31, 2018 | -23.17% |
| Dec 31, 2017 | -57.93% |
| Sep 30, 2017 | -11.21% |
| Mar 31, 2017 | 332.38% |
| Dec 31, 2016 | 24.83% |